Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Uveal Melanoma 1Neoplasm Metastasis 1Melanoma 1

Interventions

pembrolizumab 3Nivolumab 3Ipilimumab 3Cyclophosphamide 3Radiosurgery 2MART-1 Antigen 2CTLA-4 Antigen 2ulixertinib 1sotrastaurin 1siremadlin 1relatlimab 1pentetreotide 1oblimersen 1incomplete Freund's adjuvant 1fotemustine 1fludarabine phosphate 1fludarabine 1entrectinib 1defactinib 1binimetinib 1benzamide 1aldesleukin 1aflibercept 1Valacyclovir 1Toll-Like Receptor 1 1TYRP1 protein, human 1Sunitinib 1Standard of Care 1RO5126766 1RNA, Messenger 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Uveal Melanoma × fotemustine × Clear all
NCT00110123 2012-09-24

Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Terminated
171 enrolled
Dermatologic

Uveal Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡